Arexvy

Overview

respiratory syncytial virus vaccine

vaccine

• non-live vaccine

Avoid/Use Alternative

• interferon gamma 1b
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

interferon gamma 1b

1 interaction

Avoid/Use Alternative

respiratory syncytial virus vaccine + interferon gamma 1b

avoid combo: combo may result in amplified immune response (immunomodulatory effects)

Monitor/Modify Tx

• abatacept
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

abatacept

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + abatacept

if possible, vaccinate at least 2wk before starting abatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abemaciclib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

abemaciclib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + abemaciclib

if possible, vaccinate at least 2wk before starting abemaciclib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abrocitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

abrocitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + abrocitinib

if possible, vaccinate at least 2wk before starting abrocitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• acalabrutinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

acalabrutinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + acalabrutinib

if possible, vaccinate at least 2wk before starting acalabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• adalimumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

adalimumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + adalimumab

if possible, vaccinate at least 2wk before starting adalimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• afamitresgene autoleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + afamitresgene autoleucel

if possible, vaccinate at least 2wk before starting afamitresgene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• aldesleukin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

aldesleukin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + aldesleukin

if possible, vaccinate at least 2wk before starting aldesleukin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• alemtuzumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

alemtuzumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + alemtuzumab

if possible, vaccinate at least 2wk before starting alemtuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anakinra
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

anakinra

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + anakinra

if possible, vaccinate at least 2wk before starting anakinra tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anifrolumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

anifrolumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + anifrolumab

if possible, vaccinate at least 2wk before starting anifrolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atezolizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

atezolizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + atezolizumab

if possible, vaccinate at least 2wk before starting atezolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atidarsagene autotemcel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + atidarsagene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• avelumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

avelumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + avelumab

if possible, vaccinate at least 2wk before starting avelumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• axicabtagene ciloleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + axicabtagene ciloleucel

if possible, vaccinate at least 2wk before starting axicabtagene ciloleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azacitidine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

azacitidine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + azacitidine

if possible, vaccinate at least 2wk before starting azacitidine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azathioprine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

azathioprine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + azathioprine

if possible, vaccinate at least 2wk before starting azathioprine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• baricitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

baricitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + baricitinib

if possible, vaccinate at least 2wk before starting baricitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• basiliximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

basiliximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + basiliximab

if possible, vaccinate at least 2wk before starting basiliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belatacept
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

belatacept

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + belatacept

if possible, vaccinate at least 2wk before starting belatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belimumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

belimumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + belimumab

if possible, vaccinate at least 2wk before starting belimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belinostat
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

belinostat

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + belinostat

if possible, vaccinate at least 2wk before starting belinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bendamustine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

bendamustine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + bendamustine

if possible, vaccinate at least 2wk before starting bendamustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• betamethasone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

betamethasone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + betamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• bimekizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

bimekizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + bimekizumab

if possible, vaccinate at least 2wk before starting bimekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• blinatumomab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

blinatumomab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + blinatumomab

if possible, vaccinate at least 2wk before starting blinatumomab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bortezomib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

bortezomib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + bortezomib

if possible, vaccinate at least 2wk before starting bortezomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brentuximab vedotin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + brentuximab vedotin

if possible, vaccinate at least 2wk before starting brentuximab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brexucabtagene autoleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + brexucabtagene autoleucel

if possible, vaccinate at least 2wk before starting brexucabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brodalumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

brodalumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + brodalumab

if possible, vaccinate at least 2wk before starting brodalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

budesonide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + budesonide

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide rectal
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

budesonide rectal

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + budesonide rectal

consider vaccinating at least 2wk before budesonide rectal use; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• busulfan
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

busulfan

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + busulfan

if possible, vaccinate at least 2wk before starting busulfan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cabazitaxel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cabazitaxel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cabazitaxel

if possible, vaccinate at least 2wk before starting cabazitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• canakinumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

canakinumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + canakinumab

if possible, vaccinate at least 2wk before starting canakinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capecitabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

capecitabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + capecitabine

if possible, vaccinate at least 2wk before starting capecitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carboplatin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

carboplatin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + carboplatin

if possible, vaccinate at least 2wk before starting carboplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carfilzomib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

carfilzomib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + carfilzomib

if possible, vaccinate at least 2wk before starting carfilzomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carmustine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

carmustine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + carmustine

if possible, vaccinate at least 2wk before starting carmustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cemiplimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cemiplimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cemiplimab

if possible, vaccinate at least 2wk before starting cemiplimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• certolizumab pegol
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + certolizumab pegol

if possible, vaccinate at least 2wk before starting certolizumab pegol tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorambucil
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

chlorambucil

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + chlorambucil

if possible, vaccinate at least 2wk before starting chlorambucil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ciltacabtagene autoleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ciltacabtagene autoleucel

if possible, vaccinate at least 2wk before starting ciltacabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cisplatin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cisplatin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cisplatin

if possible, vaccinate at least 2wk before starting cisplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine injection
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cladribine injection

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cladribine injection

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine oral
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cladribine oral

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cladribine oral

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• clofarabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

clofarabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + clofarabine

if possible, vaccinate at least 2wk before starting clofarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• copanlisib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

copanlisib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + copanlisib

if possible, vaccinate at least 2wk before starting copanlisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• corticotropin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

corticotropin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + corticotropin

if possible, vaccinate at least 2wk before starting corticotropin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cortisone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cortisone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• cosibelimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cosibelimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cosibelimab

if possible, vaccinate at least 2wk before starting cosibelimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cyclophosphamide

if possible, vaccinate at least 2wk before starting cyclophosphamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclosporine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cyclosporine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cyclosporine

if possible, vaccinate at least 2wk before starting cyclosporine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cytarabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

cytarabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + cytarabine

if possible, vaccinate at least 2wk before starting cytarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dactinomycin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dactinomycin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dactinomycin

if possible, vaccinate at least 2wk before starting dactinomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daratumumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

daratumumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + daratumumab

if possible, vaccinate at least 2wk before starting daratumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dasatinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dasatinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dasatinib

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daunorubicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

daunorubicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + daunorubicin

if possible, vaccinate at least 2wk before starting daunorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• decitabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

decitabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + decitabine

if possible, vaccinate at least 2wk before starting decitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deflazacort
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

deflazacort

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + deflazacort

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• deucravacitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

deucravacitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + deucravacitinib

if possible, vaccinate at least 2wk before starting deucravacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deuruxolitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + deuruxolitinib

if possible, vaccinate at least 2wk before starting deuruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dexamethasone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dexamethasone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dexamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• dimethyl fumarate
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dimethyl fumarate

if possible, vaccinate at least 2wk before starting dimethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dinutuximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dinutuximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dinutuximab

if possible, vaccinate at least 2wk before starting dinutuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diroximel fumarate
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + diroximel fumarate

if possible, vaccinate at least 2wk before starting diroximel fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• docetaxel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

docetaxel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + docetaxel

if possible, vaccinate at least 2wk before starting docetaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dostarlimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dostarlimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dostarlimab

if possible, vaccinate at least 2wk before starting dostarlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• doxorubicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

doxorubicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + doxorubicin

if possible, vaccinate at least 2wk before starting doxorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dupilumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

dupilumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + dupilumab

if possible, vaccinate at least 2wk before starting dupilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• durvalumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

durvalumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + durvalumab

if possible, vaccinate at least 2wk before starting durvalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• duvelisib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

duvelisib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + duvelisib

if possible, vaccinate at least 2wk before starting duvelisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• efgartigimod alfa
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

efgartigimod alfa

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + efgartigimod alfa

if possible, vaccinate at least 2wk before starting efgartigimod alfa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elivaldogene autotemcel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + elivaldogene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• elotuzumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

elotuzumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + elotuzumab

if possible, vaccinate at least 2wk before starting elotuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elranatamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

elranatamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + elranatamab

if possible, vaccinate at least 2wk before starting elranatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• emapalumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

emapalumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + emapalumab

if possible, vaccinate at least 2wk before starting emapalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epcoritamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

epcoritamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + epcoritamab

if possible, vaccinate at least 2wk before starting epcoritamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epirubicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

epirubicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + epirubicin

if possible, vaccinate at least 2wk before starting epirubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• eribulin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

eribulin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + eribulin

if possible, vaccinate at least 2wk before starting eribulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etanercept
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

etanercept

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + etanercept

if possible, vaccinate at least 2wk before starting etanercept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etoposide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

etoposide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + etoposide

if possible, vaccinate at least 2wk before starting etoposide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etrasimod
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

etrasimod

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + etrasimod

if possible, vaccinate at least 2wk before starting etrasimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• everolimus
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

everolimus

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + everolimus

if possible, vaccinate at least 2wk before starting everolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fingolimod
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

fingolimod

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + fingolimod

if possible, vaccinate at least 2wk before starting fingolimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• floxuridine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

floxuridine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + floxuridine

if possible, vaccinate at least 2wk before starting floxuridine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludarabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

fludarabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + fludarabine

if possible, vaccinate at least 2wk before starting fludarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludrocortisone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

fludrocortisone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + fludrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• fluorouracil
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

fluorouracil

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + fluorouracil

if possible, vaccinate at least 2wk before starting fluorouracil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fruquintinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

fruquintinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + fruquintinib

if possible, vaccinate at least 2wk before starting fruquintinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemcitabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

gemcitabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + gemcitabine

if possible, vaccinate at least 2wk before starting gemcitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemtuzumab ozogamicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + gemtuzumab ozogamicin

if possible, vaccinate at least 2wk before starting gemtuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• glofitamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

glofitamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + glofitamab

if possible, vaccinate at least 2wk before starting glofitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• golimumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

golimumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + golimumab

if possible, vaccinate at least 2wk before starting golimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• guselkumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

guselkumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + guselkumab

if possible, vaccinate at least 2wk before starting guselkumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

hydrocortisone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + hydrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

hydroxyurea

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + hydroxyurea

if possible, vaccinate at least 2wk before starting hydroxyurea tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibritumomab tiuxetan
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ibritumomab tiuxetan

if possible, vaccinate at least 2wk before starting ibritumomab tiuxetan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibrutinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ibrutinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ibrutinib

if possible, vaccinate at least 2wk before starting ibrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idarubicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

idarubicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + idarubicin

if possible, vaccinate at least 2wk before starting idarubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idecabtagene vicleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + idecabtagene vicleucel

if possible, vaccinate at least 2wk before starting idecabtagene vicleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idelalisib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

idelalisib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + idelalisib

if possible, vaccinate at least 2wk before starting idelalisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ifosfamide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ifosfamide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ifosfamide

if possible, vaccinate at least 2wk before starting ifosfamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imatinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

imatinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + imatinib

if possible, vaccinate at least 2wk before starting imatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inebilizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

inebilizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + inebilizumab

if possible, vaccinate at least 4wk before starting inebilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• infliximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

infliximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + infliximab

if possible, vaccinate at least 2wk before starting infliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + inotuzumab ozogamicin

if possible, vaccinate at least 2wk before starting inotuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ipilimumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ipilimumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ipilimumab

if possible, vaccinate at least 2wk before starting ipilimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• irinotecan
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

irinotecan

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + irinotecan

if possible, vaccinate at least 2wk before starting irinotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• isatuximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

isatuximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + isatuximab

if possible, vaccinate at least 2wk before starting isatuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixabepilone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ixabepilone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ixabepilone

if possible, vaccinate at least 2wk before starting ixabepilone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixekizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ixekizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ixekizumab

if possible, vaccinate at least 2wk before starting ixekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lebrikizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

lebrikizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + lebrikizumab

if possible, vaccinate at least 2wk before starting lebrikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• leflunomide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

leflunomide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + leflunomide

if possible, vaccinate at least 2wk before starting leflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lenalidomide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

lenalidomide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + lenalidomide

if possible, vaccinate at least 2wk before starting lenalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lisocabtagene maraleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + lisocabtagene maraleucel

if possible, vaccinate at least 2wk before starting lisocabtagene maraleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lomustine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

lomustine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + lomustine

if possible, vaccinate at least 2wk before starting lomustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• loncastuximab tesirine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + loncastuximab tesirine

if possible, vaccinate at least 2wk before starting loncastuximab tesirine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + lymphocyte immune globulin, anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• melphalan
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

melphalan

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + melphalan

if possible, vaccinate at least 2wk before starting melphalan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mercaptopurine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mercaptopurine

if possible, vaccinate at least 2wk before starting mercaptopurine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methotrexate
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

methotrexate

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + methotrexate

if possible, vaccinate at least 2wk before starting methotrexate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methylprednisolone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

methylprednisolone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + methylprednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• mirikizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mirikizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mirikizumab

if possible, vaccinate at least 2wk before starting mirikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitoxantrone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mitoxantrone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mitoxantrone

if possible, vaccinate at least 2wk before starting mitoxantrone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mogamulizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mogamulizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mogamulizumab

if possible, vaccinate at least 2wk before starting mogamulizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• momelotinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

momelotinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + momelotinib

if possible, vaccinate at least 2wk before starting momelotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• monomethyl fumarate
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + monomethyl fumarate

if possible, vaccinate at least 2wk before starting monomethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mosunetuzumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mosunetuzumab

if possible, vaccinate at least 2wk before starting mosunetuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolate mofetil
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mycophenolate mofetil

if possible, vaccinate at least 2wk before starting mycophenolate mofetil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolic acid
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + mycophenolic acid

if possible, vaccinate at least 2wk before starting mycophenolic acid tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• natalizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

natalizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + natalizumab

if possible, vaccinate at least 2wk before starting natalizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nelarabine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

nelarabine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + nelarabine

if possible, vaccinate at least 2wk before starting nelarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nemolizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

nemolizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + nemolizumab

if possible, vaccinate at least 2wk before starting nemolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nivolumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

nivolumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + nivolumab

if possible, vaccinate at least 2wk before starting nivolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obecabtagene autoleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + obecabtagene autoleucel

if possible, vaccinate at least 2wk before starting obecabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obinutuzumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

obinutuzumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + obinutuzumab

if possible, vaccinate at least 2wk before starting obinutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ocrelizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ocrelizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ocrelizumab

if possible, vaccinate at least 2wk before starting ocrelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ofatumumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ofatumumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ofatumumab

if possible, vaccinate at least 2wk before starting ofatumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• omacetaxine mepesuccinate
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

omacetaxine mepesuccinate

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + omacetaxine mepesuccinate

if possible, vaccinate at least 2wk before starting omacetaxine mepesuccinate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• oxaliplatin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

oxaliplatin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + oxaliplatin

if possible, vaccinate at least 2wk before starting oxaliplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ozanimod
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ozanimod

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ozanimod

if possible, vaccinate at least 2wk before starting ozanimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• paclitaxel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

paclitaxel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + paclitaxel

if possible, vaccinate at least 2wk before starting paclitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• panobinostat
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

panobinostat

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + panobinostat

if possible, vaccinate at least 2wk before starting panobinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• peginterferon alfa 2a
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + peginterferon alfa 2a

if possible, vaccinate at least 2wk before starting peginterferon alfa 2a tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pembrolizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

pembrolizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + pembrolizumab

if possible, vaccinate at least 2wk before starting pembrolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pentostatin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

pentostatin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + pentostatin

if possible, vaccinate at least 2wk before starting pentostatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pirtobrutinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + pirtobrutinib

if possible, vaccinate at least 2wk before starting pirtobrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• polatuzumab vedotin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + polatuzumab vedotin

if possible, vaccinate at least 2wk before starting polatuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

pomalidomide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + pomalidomide

if possible, vaccinate at least 2wk before starting pomalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ponatinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ponatinib

if possible, vaccinate at least 2wk before starting ponatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponesimod
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ponesimod

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ponesimod

if possible, vaccinate at least 2wk before starting ponesimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisolone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

prednisolone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + prednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

prednisone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + prednisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• procarbazine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

procarbazine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + procarbazine

if possible, vaccinate at least 2wk before starting procarbazine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• regorafenib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

regorafenib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + regorafenib

if possible, vaccinate at least 2wk before starting regorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• retifanlimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

retifanlimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + retifanlimab

if possible, vaccinate at least 2wk before starting retifanlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilonacept
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

rilonacept

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + rilonacept

if possible, vaccinate at least 2wk before starting rilonacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• risankizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

risankizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + risankizumab

if possible, vaccinate at least 2wk before starting risankizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ritlecitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ritlecitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ritlecitinib

if possible, vaccinate at least 2wk before starting ritlecitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rituximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

rituximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + rituximab

vaccinate at least 4wk before starting rituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• romidepsin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

romidepsin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + romidepsin

if possible, vaccinate at least 2wk before starting romidepsin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ropeginterferon alfa-2b
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ropeginterferon alfa-2b

if possible, vaccinate at least 2wk before starting ropeginterferon alfa-2b tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rozanolixizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

rozanolixizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + rozanolixizumab

if possible, vaccinate at least 2wk before starting rozanolixizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ruxolitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ruxolitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ruxolitinib

if possible, vaccinate at least 2wk before starting ruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sarilumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

sarilumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + sarilumab

if possible, vaccinate at least 2wk before starting sarilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• satralizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

satralizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + satralizumab

if possible, vaccinate at least 2wk before starting satralizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• secukinumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

secukinumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + secukinumab

if possible, vaccinate at least 2wk before starting secukinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selinexor
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

selinexor

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + selinexor

if possible, vaccinate at least 2wk before starting selinexor tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siltuximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

siltuximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + siltuximab

if possible, vaccinate at least 2wk before starting siltuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siponimod
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

siponimod

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + siponimod

if possible, vaccinate at least 2wk before starting siponimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

sirolimus

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + sirolimus

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus albumin-bound
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + sirolimus albumin-bound

if possible, vaccinate at least 2wk before starting sirolimus albumin-bound tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus topical
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

sirolimus topical

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + sirolimus topical

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• spesolimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

spesolimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + spesolimab

if possible, vaccinate at least 2wk before starting spesolimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

sunitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + sunitinib

if possible, vaccinate at least 2wk before starting sunitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tacrolimus
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tacrolimus

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tacrolimus

if possible, vaccinate at least 2wk before starting tacrolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tafasitamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tafasitamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tafasitamab

if possible, vaccinate at least 2wk before starting tafasitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• talquetamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

talquetamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + talquetamab

if possible, vaccinate at least 2wk before starting talquetamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tarlatamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tarlatamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tarlatamab

if possible, vaccinate at least 2wk before starting tarlatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teclistamab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

teclistamab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + teclistamab

if possible, vaccinate at least 2wk before starting teclistamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temozolomide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

temozolomide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + temozolomide

if possible, vaccinate at least 2wk before starting temozolomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temsirolimus
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

temsirolimus

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + temsirolimus

if possible, vaccinate at least 2wk before starting temsirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teplizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

teplizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + teplizumab

vaccinate at least 2wk before or 6wk after teplizumab tx; otherwise, consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• teriflunomide
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

teriflunomide

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + teriflunomide

if possible, vaccinate at least 2wk before starting teriflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thioguanine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

thioguanine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + thioguanine

if possible, vaccinate at least 2wk before starting thioguanine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thiotepa
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

thiotepa

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + thiotepa

if possible, vaccinate at least 2wk before starting thiotepa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tildrakizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tildrakizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tildrakizumab

if possible, vaccinate at least 2wk before starting tildrakizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tisagenlecleucel
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tisagenlecleucel

if possible, vaccinate at least 2wk before starting tisagenlecleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tislelizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tislelizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tislelizumab

if possible, vaccinate at least 2wk before starting tislelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tocilizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tocilizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tocilizumab

if possible, vaccinate at least 2wk before starting tocilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tofacitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tofacitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tofacitinib

if possible, vaccinate at least 2wk before starting tofacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• topotecan
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

topotecan

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + topotecan

if possible, vaccinate at least 2wk before starting topotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• toripalimab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

toripalimab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + toripalimab

if possible, vaccinate at least 2wk before starting toripalimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tralokinumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tralokinumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tralokinumab

if possible, vaccinate at least 2wk before starting tralokinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tremelimumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

tremelimumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + tremelimumab

if possible, vaccinate at least 2wk before starting tremelimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• triamcinolone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

triamcinolone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + triamcinolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• ublituximab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ublituximab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ublituximab

if possible, vaccinate at least 2wk before starting ublituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

upadacitinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + upadacitinib

if possible, vaccinate at least 2wk before starting upadacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ustekinumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

ustekinumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + ustekinumab

if possible, vaccinate at least 2wk before starting ustekinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vamorolone
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

vamorolone

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + vamorolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• vedolizumab
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

vedolizumab

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + vedolizumab

if possible, vaccinate at least 2wk before starting vedolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• venetoclax
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

venetoclax

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + venetoclax

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinblastine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

vinblastine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + vinblastine

if possible, vaccinate at least 2wk before starting vinblastine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vincristine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

vincristine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + vincristine

if possible, vaccinate at least 2wk before starting vincristine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinorelbine
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

vinorelbine

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + vinorelbine

if possible, vaccinate at least 2wk before starting vinorelbine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• voclosporin
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

voclosporin

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + voclosporin

if possible, vaccinate at least 2wk before starting voclosporin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanubrutinib
Arexvy (respiratory syncytial virus vaccine, adjuvanted (RSV))

+

zanubrutinib

1 interaction

Monitor/Modify Tx

respiratory syncytial virus vaccine + zanubrutinib

if possible, vaccinate at least 2wk before starting zanubrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)